

The information in this press release is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, South Africa, Switzerland or Singapore.

Press release December 4th, 2009

Press release from the extraordinary shareholders' meeting of Biovitrum (publ)

At the extraordinary shareholders' meeting held on December 4th, 2009, resolutions on the approval of the board's resolution regarding the acquisition of Swedish Orphan International Holding AB and of the board's resolution on a rights issue as well as on an authorization for the board to resolve on an issue of common shares and convertible participating certificates (*konvertibla vinstandelsbevis*) against payment in kind or by way of set-off, were adopted. In order to enable the rights issue the meeting also resolved to amend the articles of association. Further, a new board member and a new deputy chairman of the board of directors were elected.

All resolutions by the meeting were caused by the agreement between Biovitrum and the shareholders of Swedish Orphan International Holding AB ("Swedish Orphan") pursuant to which Biovitrum shall acquire 100 per cent of the shares and warrants in Swedish Orphan (the "Transaction").

Read the whole press release at:

<http://www.biovitrum.com/templates/InformationPage.aspx?id=818>

For further information, please contact:

Biovitrum AB (publ)

Martin Nicklasson, CEO Biovitrum
Phone: +46 8 697 20 00

Göran Arvidson, CFO Biovitrum
Phone: +46 70 633 30 42

Erik Kinnman, VP Investor Relations Biovitrum
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com



About Biovitrum

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. Biovitrum has revenues of approximately SEK 1.2 billion and approximately 400 employees (prior to the Transaction). Biovitrum's head office is located in Sweden and the share is listed on the NASDAQ OMX Stockholm. For more information please visit www.biovitrum.com.

IMPORTANT NOTICE:

The information in this press release is not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, South Africa, Switzerland or Singapore.

The information in this press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

The information in this press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the "Securities Act"). The securities mentioned herein may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offer of securities in the United States.

The information in this press release may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 5.15 p.m. (CET) on December 4th, 2009.